Apicore Pharmaceuticals

RK Pharma Inc Analysis

RK Pharma Inc, with its slogan "We are a US based company focused on the manufacturing high quality and affordable generic pharmaceutical products," is a privately held US-based company founded in 2018. The company specializes in the development, manufacturing, and sale of high-quality and affordable generic pharmaceutical products worldwide.

One of the key strengths of RK Pharma Inc is its uniquely integrated development, regulatory, and manufacturing capabilities, with a particular focus on products with formulation challenges and first generic opportunities. The company's state-of-the-art facility in Pearl River, New York, is dedicated to managing bulk manufacturing, multi-format packaging, and end-product release testing, particularly for injectables, sterile ophthalmic, and dermal products.

Furthermore, RK Pharma Inc also has a subsidiary, Apicore LLC, which has been a leading process R&D and API manufacturing service provider for the worldwide pharmaceutical industry since 2003. The company offers a wide portfolio of services, including APIs for the generic industry and custom synthesis for early-phase pharmaceutical research and branded products.

Notably, RK Pharma Inc's USFDA approved facilities in India, located in Visakhapatnam, Andhra Pradesh, and Vadodara, Gujarat, are equipped with state-of-the-art analytical and research capabilities. As of 06 June 2023, the company received a $200.00 million Private Equity Round investment from PAG. It is also worth mentioning that the company's pipeline of products is set to be commercialized in the United States by its subsidiary, Archis Pharma LLC.

Overall, with its strong focus on high-quality and affordable generic pharmaceutical products, integrated capabilities, and significant investment, RK Pharma Inc presents itself as a promising player in the Health Care, Manufacturing, and Pharmaceutical industries, solidifying its position as a key player in the pharmaceutical manufacturing sector.